News

NRTX-1001 will be first evaluated in an open-label dose-escalation study, followed by a randomized blinded portion, with both featuring patients with drug-resistant mesial temporal epilepsy.

Marisa McGinley, DO, offered her perspective on the use of telemedicine in the management of patients with MS, summarizing the benefits it provides and the challenges that remain as it is more increasingly incorporated into care.

A total of 12 studies evaluating children and adolescents with nonepileptic seizures were included, with both top-down and bottom-up approaches employed.

The professor of neurology at the NYU Grossman School of Medicine provided his thoughts on the most notable strides within the multiple sclerosis field in the past year. [WATCH TIME: 3 minutes]

The PHOENIX study is a follow-up study to CENTAUR, a phase 2/3 study that demonstrated AMX0035’s ability to improve survival rate in patients with ALS.

The director of the Multiple Sclerosis Achievement Center in Sacramento discussed 3-year data from an assessment of the program, outlining key findings and future research efforts. [WATCH TIME: 6 minutes]

Here's what is coming soon to NeurologyLive.

A total of 14 children and their mothers were evaluated in the study, and although improvements in sleep scores were also reported, they were not statistically significant.

The association between white matter hyperintensity remained significant even after controlling for vascular risk factors and diseases.

Even after adjusting for the presence of diabetes, rivaroxaban remained associated with a lower risk of recurrent stroke or systemic embolism.

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic shared her perspective on the use of telemedicine in MS care, what challenges it can address, and the need to optimize its use. [WATCH TIME: 6 minutes]

Included participants were enrolled in Medicaid, which includes some of the most vulnerable patients in this population, investigators said.

Neurology News Network for the week ending November 6, 2021.

The chief of the Multiple Sclerosis Division at the Perelman School of Medicine, University of Pennsylvania, discussed recommendations for COVID-19 vaccination in this patient population, specifically for those on disease-modifying therapies. [WATCH TIME: 2 minutes]

Mona Bostick, RDN, LDN, MSCS, gave her perspective on nutrition in MS, popular elimination diets, and the role registered dietitians can play in the multidisciplinary care model.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 5, 2021.

The director of the Multiple Sclerosis Achievement Center outlined the design of the wellness programs, which are held in 2 different formats. [WATCH TIME: 4 minutes]

Expert clinicians offer their perspectives on the ongoing shortage of neurologists, stigmas associated with migraine, diets for those with epilepsy, mesenchymal stem cells in MS, and other topics.

Robert Fox, MD, discussed what’s currently available in terms of cannabis-derived medications that treat symptoms of multiple sclerosis, and realistic possibility of another soon entering the market.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Victor Sung, MD.

Repeated analyses using both 3-mm and 1-mm diameter macular data—narrower volumes than standard—showed no relevant outer plexiform layer or outer nuclear layer thinning in those with seropositive AQP4-IgG.

Amit Bar-Or, MD, FRCPC, FAAN, FANA, commented on his presentations at CMSC 2021, one of which focused on COVID-19 vaccination, which experts do not believe poses risks for those on disease-modifying therapies.

The staff member at the Mellen Center for Multiple Sclerosis discussed reasons why patients may stop treatment, as well as strategies for maintaining communication with the healthcare team in the event of discontinuation. [WATCH TIME: 5 minutes]

Performing physical activity after receiving a diagnosis of Parkinson disease was associated with a decreased mortality rate, even in individuals with PD who were physically inactive before diagnosis.

An expert provided thoughts on the state of multiple sclerosis research, where the efforts have been directed recently, and areas that need increased focus.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

The Renew Biosciences device is designed to enhance circulation and improve cerebrovascular health by stimulating the physiological effects of exercise and the function of endothelial cells.

Brian Hutchinson, PT, MSCS, commented on the Multiple Sclerosis Achievement Center program, which includes patient data spanning a 3-year period.

The associate professor of pediatrics and neurology at Rutgers–Robert Wood Johnson Medical School commented on the need to recognize when adolescent patients are ready to learn more about their condition. [WATCH TIME: 5 minutes]

Through 36 weeks of treatment with CNM-Au8, investigators observed a slowing of disease progression and decreased number of participants with a 6-point decline on ALSFRS-R.